Transcatheter Arterial Chemoembolization Combined with Percutaneous Treatment of Liver Tumor Injection in Advanced Liver Cancer

Objective: To discuss and analyze the factors affecting long-term survival after simultaneous treatment with 2 kinds of therapy for patients with unresectable mid and late stage liver cancer.Methods: Twenty-seven cases had unresectable mid and late stage liver cancer.The 10 cases in stage Ⅲ accounted for 37.1%; 17 cases in stages Ⅱ～Ⅲ accounted for 62.9%; diseases affecting 2 or more important organs were 24 cases,accounting for 88.9%.The liver cancer focus diameters were 9.5～13 cm; 1 case of liver cancer that had a focus diameter of 5.3×2.6×2.4 cm accounted for 3.7%.Treatments were as follows:①PCTI,ethyl alcohol and zymoplasm 2 +TACE was given 1 time (7 cases);② PCTI,r-INF,TNF, ethyl alcohol and zymoplasm 2+TACE was given 1 time (5 cases);③ PCTI,SST and above pharmacological treatment 3+ TACE was given 1 time (6 cases); ④ PCTI card platinum,taxus mellow,SST,r-INF,TNF,ethyl alcohol and zymoplasm 3 + TACE was given 2 times (6 cases);⑤ PCTI applied above pharmacological treatment 7 +TACE was given 3 times (3 cases). Results: For each treatment group survival time was as follows:① Max.426 days,min.241 days;② max 634 days, min.368 days;③ max.869 days,min.612 days;④ max 1461 days,min.873 days;⑤ max.2,556 days (above 7 years), min.1096 days.Conclusion: The main factors for curative effects include unresectable mid and late stage liver cancer occurring with hepatitis,liver cirrhosis,the portal vein hyperbarism and serious cardiopulmonary kidney disease.Moreover, the number of therapies used simultaneously,as well as the number of multiple medications,are also important factors affecting the cure of this disease.